No abstract

HLA‐DQB1*03:01:01:21Q differs from HLA‐DQB1*03:01:01:03 by a single‐nucleotide substitution (G → A) at position 1 of intron 3.

Background: Vaccines against SARS-CoV-2 have provided an invaluable resource in the fight against this infection. Given the current vaccine shortage, vaccination programs must prioritize their distribution to the most appropriate segments of the population. Methods: We carried out a prospective cohort study with 63 health care workers (HCWs) from a public General Hospital. We compared antibody responses to two doses of BNT162b2 mRNA Covid-19 vaccine between HCWs with laboratory-confirmed SARS-CoV-2 infection before vaccination (experienced HCWs) and HCWs who were not previously infected (naive HCWs). Results: Seven days after the first vaccine dose HCWs with previous infection experienced a 126 fold increase in antibody levels (GMC 26955 AU; 95% CI 18785-35125). However, in the HCW naive group the response was much lower and only 5 of them showed positive antibody levels (>50 AU). The HCWs with previous infection did not significantly increased their antibody levels after the second dose while there was a significant increase in the naive HCW group (16 fold; GMC 20227 AU; 95% CI: 15179-25275). Approximately two months after completing vaccination, the level of antibodies was much lower in naive HCWs (GMC 6595 AU vs. 25003 AU; p<0.001) Conclusion: The study shows that 10 months after the disease has passed, the immune system is capable of producing a rapid and powerful secondary antibody response after one single dose of the vaccine. This response reflects the persistence of immunological memory and it is independent of whether or not anti-SARS-CoV-2 antibodies are detected in blood. Besides, we found that the second dose does not improve the antibody response in individuals with previous Covid-19 infection. Nonetheless, two months later, the persistence of antibody levels is still higher in the experienced HCWs. These data suggest that immune memory remains for a long time in recovered individuals, and therefore, vaccination in this group could be postponed until immunization of the rest of the population is complete.

Four novel HLA‐DPA1 alleles, ‐DPA1*01:03:01:59, ‐DPA1*01:03:01:60, ‐DPA1*02:01:01:30, and ‐DPA1*02:01:01:31, characterized in Spanish individuals.

Four novel HLA alleles, HLA‐B*40:02:01:26, HLA‐DQB1*03:01:01:29, HLA‐DQB1*04:02:01:12 and HLA‐DPB1*1195:01, detected in Spanish individuals.